结论：在这个关键的3期研究中，奥曲肽植入物通过6个月持续释放奥曲肽，维持血gh和igf—1水平降低，并且耐受性良好。
Conclusions: in this pivotal phase 3 study, the octreotide implant maintained reduced blood levels of GH and IGF-1 with continuous octreotide release over 6 months, which was well tolerated.
初期的筛分终点是12个月的左心室射血分数和左心室收缩末期容积。
The primary end points were the left ventricular ejection fraction and left ventricular end-systolic volume at 12 months.
两组受体的移植后3个月和12个月血肌酐水平无显著统计学差异。
There was no statistically significant difference between the two groups for the recipient serum creatinine levels at 3 and 12 months after transplantation.
应用推荐